Findings

What do systematic reviews say?

7 questions · 8 findings · 2 reviews · Urology

No studies found 1 · 12.5%GRADE not reported 0 · 0%Very low 1 · 12.5%Low 5 · 62.5%Moderate 1 · 12.5%High 0 · 0%

Major adverse events

Desmopressin showed no clear difference in major adverse events compared with placebo (low certainty).

2 findings from 1 review

Desmopressin for treating nocturia in men 2017 · Cochrane Headline outcomes only
RR 3.05 [0.13, 73.39]
1 study · 115 participants
Low
Desmopressin for treating nocturia in men 2017 · Cochrane Headline outcomes only
RR 0.97 [0.1, 9.03]
2 studies · 536 participants
Very low

Major adverse events

1 finding from 1 review

Desmopressin for treating nocturia in men 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 31 participants
Low

Major adverse events

Desmopressin plus alpha‐blocker showed no clear difference in major adverse events compared with alpha‐blocker (low certainty).

1 finding from 1 review

Desmopressin for treating nocturia in men 2017 · Cochrane Headline outcomes only
RR 0.3 [0.01, 7.32]
3 studies · 402 participants
Low

Major adverse events

1 finding from 1 review

Desmopressin for treating nocturia in men 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 427 participants
Low

Major adverse events

The review found no eligible studies for this question.

1 finding from 1 review

Desmopressin for treating nocturia in men 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Major adverse events · adult patients presenting with symptoms of ureteral stone disease

Alpha‐blockers showed no clear difference in major adverse events compared with standard therapy (low certainty).

1 finding from 1 review

Alpha‐blockers as medical expulsive therapy for ureteral stones 2018 · Cochrane Headline outcomes only
RR 1.25 [0.8, 1.96]
18 studies · 3124 participants
Low

Major adverse events · adult patients presenting with symptoms of ureteral stone disease

Alpha‐blockers probably leads to higher major adverse events compared with placebo (moderate certainty).

1 finding from 1 review

Alpha‐blockers as medical expulsive therapy for ureteral stones 2018 · Cochrane Headline outcomes only
RR 2.09 [1.13, 3.86]
10 studies · 1650 participants
Moderate